Market Place

Market Place

Market Place

Menu

Post Enquiry

Post Enquiry

PharmaCompass

Home

Market Place

Market Place

Search
All
API
FDF
Price
Services
Excipients
Enquiries

    Find

    • Active Pharmaceutical Ingredients Active Pharmaceutical Ingredients
    • Finished Drug Formulations Finished Drug Formulations
    • Price Price
    • Excipients Excipients
    • Services Services
    • Market Place Marketplace

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Loading...

    All Data

    Filters Filter refresh
    ×
    FILTER DATA :
    News Type filter
      Company filter
        Product Type filter
          Deal Size filter
            Upfront Payment filter
              refresh

              Product Type Full Screen

              Companies Full Screen

              ChemomAb

              • Development Update

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              ISRAEL Israel

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              BIO IMPACT

              Participation Not Confirmed

              Update your events

              Chemomab Receives European Orphan Drug Designation for CM-101 for the Treatment of Primary Sclerosing Cholangitis

              Contact the Supplier

              Lead Product(s): CM-101

              Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: CM-101

              Highest Development Status: Phase II Product Type: Large molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable August 26, 2020

              Details:

              European Commission has granted Orphan Drug Designation to Chemomab's lead drug candidate CM-101 for the treatment of Primary Sclerosing Cholangitis (PSC), based on a positive opinion from the Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency.

              Can-Fite BioPharma

              • Development Update

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              ISRAEL Israel

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              BIO IMPACT

              Participation Not Confirmed

              Update your events

              Can-Fite Receives Notification of Patent Grant from European Patent Office for Namodenoson in the Treatment of NASH

              Contact the Supplier

              Lead Product(s): Namodenoson

              Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: CF102

              Highest Development Status: Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable August 25, 2020

              Details:

              Patent claims include use of the A3 adenosine receptor (A3AR), the target of Can-Fite’s platform technology, in reducing ectopic fat accumulation particularly in fatty liver as manifested in non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH).

              ChemomAb

              • Development Update

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              ISRAEL Israel

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              BIO IMPACT

              Participation Not Confirmed

              Update your events

              Chemomab Receives Regulatory Approval to Commence a Phase II Clinical Trial for CM-101 as Treatment of Primary Sclerosing Cholangitis

              Contact the Supplier

              Lead Product(s): CM-101

              Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: CM-101

              Highest Development Status: Phase II Product Type: Large molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable July 21, 2020

              Details:

              The clinical trial is a multicenter, double-blind, placebo-controlled study designed to evaluate the safety and efficacy profile of CM-101 in adult subjects with PSC.

              Can-Fite BioPharma

              • Development Update

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              ISRAEL Israel

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              BIO IMPACT

              Participation Not Confirmed

              Update your events

              Can-Fite Announces Final Data Analysis from Phase II NASH Study

              Contact the Supplier

              Lead Product(s): Namodenoson

              Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: CF102

              Highest Development Status: Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable June 30, 2020

              Details:

              Results confirm 25 mg Namodenoson as optimal dose based on MRI-PDFF analysis and liver enzymes, reduction of liver fibrosis and resolving all cases of NASH; Namodenoson continues to demonstrate a very good safety profile after drug treatment.

              Can-Fite BioPharma

              • Development Update

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              ISRAEL Israel

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              BIO IMPACT

              Participation Not Confirmed

              Update your events

              Can-Fite Receives Notice of Allowance for Namodenoson Patent in the Treatment of NASH & NAFLD from U.S. Patent and Trademark Office

              Contact the Supplier

              Lead Product(s): Namodenoson

              Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: Undisclosed

              Highest Development Status: Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable May 21, 2020

              Details:

              Patent allowance follows compelling Phase II data showing Namodenoson resolved all cases of NASH after 12 weeks of treatment, and it reduced hepatic fibrosis and steatosis in NAFLD and NASH patients.

              Can-Fite BioPharma

              • Development Update

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              ISRAEL Israel

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              BIO IMPACT

              Participation Not Confirmed

              Update your events

              Can-Fite Reports Additional Findings from Successful Phase II NASH Study

              Contact the Supplier

              Lead Product(s): Namodenoson

              Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: Undisclosed

              Highest Development Status: Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable May 18, 2020

              Details:

              All cases of NASH significantly resolved after 12 weeks of treatment with Namodenoson 25 mg.

              Can-Fite BioPharma

              • Development Update

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              ISRAEL Israel

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              BIO IMPACT

              Participation Not Confirmed

              Update your events

              Can-Fite Reports Positive Top Line Results from its Phase II NASH Study with Namodenoson

              Contact the Supplier

              Lead Product(s): Namodenoson

              Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: Undisclosed

              Highest Development Status: Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable April 07, 2020

              Details:

              The study shows Namodenoson has therapeutic effects with a good safety profile and is a very strong candidate for continued clinical development in the treatment of NAFLD/NASH.

              ChemomAb

              • Development Update

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              ISRAEL Israel

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              BIO IMPACT

              Participation Not Confirmed

              Update your events

              ChemomAb Ltd. Announces Issuance of Composition of Matter Patent for CM-101 and Reinforces its IP Portfolio

              Contact the Supplier

              Lead Product(s): CM-101

              Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: Undisclosed

              Highest Development Status: Phase II Product Type: Large molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable February 19, 2020

              Details:

              CM-101 composition of matter patent was issued by US, Japan and China Patent and Trademark Offices (patents 10,246,508, 10,479,830, 6553075, ZL 201580011755.4)

              Can-Fite BioPharma

              • Deals

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              ISRAEL Israel

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              BIO IMPACT

              Participation Not Confirmed

              Update your events

              Can-Fite Granted Patent Allowance for Namodenoson in South Korea

              Contact the Supplier

              Lead Product(s): Namodenoson

              Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: Undisclosed

              Highest Development Status: Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: Chong Kun Dang Pharm

              Deal Size: $8.0 million Upfront Cash: $6.0 million

              Deal Type: Licensing Agreement February 18, 2020

              Details:

              Chong Kun Dang Pharmaceuticals (CKD) of South Korea, has licensed the distribution rights to Namodenoson in South Korea for the treatment of liver cancer and NASH.

              PharmaCompass__DigitalAd